Should Biogen Buy Alkermes? Post author:Sam Post published:February 27, 2018 Post category:BioPharma After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making. Source: BioSpace You Might Also Like Death Count Rises for Patients on Dynavax's Hep B Vaccine But Overall Rate Was Low, Says the FDA July 25, 2017 Patient Deaths Prompt the FDA to Suspend Three of Merck & Co.'s Keytruda Trials July 5, 2017 Bristol-Myers Squibb Loses $4.3 Billion in Market Value After ASCO Update June 6, 2017
Death Count Rises for Patients on Dynavax's Hep B Vaccine But Overall Rate Was Low, Says the FDA July 25, 2017
